NCT05294666View on ClinicalTrials.gov

Evaluation of 0.05% CsA and 0.1% FK506 Eye Drops in Ocular GVHD Treatment

PHASE4CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

April 1, 2020

Primary Completion Date

June 1, 2021

Study Completion Date

July 1, 2021

Conditions
Graft Versus Host Disease in Eye
Interventions
DRUG

Cyclosporine

The chronic ocular GVHD patients in cyclosporine group received local 0.05% cyclosporine 4 times/day for 3 months, and then changed to 0.05% cyclosporine for 2 times/day for 3 months

DRUG

tacrolimus

The chronic ocular GVHD patients in tacrolimus group received local 0.05% tacrolimus 2 times/day for 3 months, and then changed to 0.05% cyclosporine for 2 times/day for 3 months

Trial Locations (1)

100000

Peking University Third Hospital, Beijing

All Listed Sponsors
lead

Peking University Third Hospital

OTHER

NCT05294666 - Evaluation of 0.05% CsA and 0.1% FK506 Eye Drops in Ocular GVHD Treatment | Biotech Hunter | Biotech Hunter